These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 26852841)
1. Exploring the Phase Behavior of Monoolein/Oleic Acid/Water Systems for Enhanced Donezepil Administration for Alzheimer Disease Treatment. Ruela AL; Carvalho FC; Pereira GR J Pharm Sci; 2016 Jan; 105(1):71-7. PubMed ID: 26852841 [TBL] [Abstract][Full Text] [Related]
2. Molecularly imprinted microparticles in lipid-based formulations for sustained release of donepezil. Ruela AL; de Figueiredo EC; de Araújo MB; Carvalho FC; Pereira GR Eur J Pharm Sci; 2016 Oct; 93():114-22. PubMed ID: 27519666 [TBL] [Abstract][Full Text] [Related]
3. Effect of fatty acids on the transdermal delivery of donepezil: in vitro and in vivo evaluation. Choi J; Choi MK; Chong S; Chung SJ; Shim CK; Kim DD Int J Pharm; 2012 Jan; 422(1-2):83-90. PubMed ID: 22037444 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Zhang P; Chen L; Gu W; Xu Z; Gao Y; Li Y Biomaterials; 2007 Apr; 28(10):1882-8. PubMed ID: 17196249 [TBL] [Abstract][Full Text] [Related]
5. The liquid crystalline phase behaviour of a nasal formulation modifies the brain disposition of donepezil in rats in the treatment of Alzheimer's disease. de Souza IFF; Dos Santos TQ; Placido RV; Mangerona BA; Carvalho FC; Boralli VB; Ruela ALM; Pereira GR Colloids Surf B Biointerfaces; 2021 Jul; 203():111721. PubMed ID: 33798905 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors. Darreh-Shori T; Hosseini SM; Nordberg A J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282 [TBL] [Abstract][Full Text] [Related]
7. Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib: Characterization, In Vitro Drug Release, and In Vivo Studies. Dante MCL; Borgheti-Cardoso LN; Fantini MCA; Praça FSG; Medina WSG; Pierre MBR; Lara MG J Pharm Sci; 2018 Mar; 107(3):870-878. PubMed ID: 29108729 [TBL] [Abstract][Full Text] [Related]
8. Interactions of biomacromolecules with reverse hexagonal liquid crystals: drug delivery and crystallization applications. Libster D; Aserin A; Garti N J Colloid Interface Sci; 2011 Apr; 356(2):375-86. PubMed ID: 21315366 [TBL] [Abstract][Full Text] [Related]
9. Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A. Lopes LB; Ferreira DA; de Paula D; Garcia MT; Thomazini JA; Fantini MC; Bentley MV Pharm Res; 2006 Jun; 23(6):1332-42. PubMed ID: 16715364 [TBL] [Abstract][Full Text] [Related]
10. A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Arai H; Takahashi T Am J Geriatr Psychiatry; 2009 Apr; 17(4):353-4. PubMed ID: 19307864 [No Abstract] [Full Text] [Related]
11. Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies. Estracanholli EA; Praça FS; Cintra AB; Pierre MB; Lara MG AAPS PharmSciTech; 2014 Dec; 15(6):1468-75. PubMed ID: 24980082 [TBL] [Abstract][Full Text] [Related]
12. Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report. Na HR; Kim S; Choi SH; Yang DW; Bae HJ; Kim JE; Park MY; Shim YS; Kim BK; Kwon JC; Yoo BG; Kim BC; Lee JS Geriatr Gerontol Int; 2011 Jan; 11(1):90-7. PubMed ID: 20825496 [TBL] [Abstract][Full Text] [Related]
13. A novel approach to enhance the mucoadhesion of lipid drug nanocarriers for improved drug delivery to the buccal mucosa. Du JD; Liu Q; Salentinig S; Nguyen TH; Boyd BJ Int J Pharm; 2014 Aug; 471(1-2):358-65. PubMed ID: 24879939 [TBL] [Abstract][Full Text] [Related]
14. Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer's Disease: in vitro and ex vivo Characterization. Espinoza LC; Vacacela M; Clares B; Garcia ML; Fabrega MJ; Calpena AC CNS Neurol Disord Drug Targets; 2018 Apr; 17(1):43-53. PubMed ID: 29299992 [TBL] [Abstract][Full Text] [Related]
15. Controlled release of donepezil intercalated in smectite clays. Park JK; Choy YB; Oh JM; Kim JY; Hwang SJ; Choy JH Int J Pharm; 2008 Jul; 359(1-2):198-204. PubMed ID: 18502063 [TBL] [Abstract][Full Text] [Related]
17. Self-assembled nanostructures of fully hydrated monoelaidin-elaidic acid and monoelaidin-oleic acid systems. Yaghmur A; Sartori B; Rappolt M Langmuir; 2012 Jul; 28(26):10105-19. PubMed ID: 22690845 [TBL] [Abstract][Full Text] [Related]
18. Biopolymer-based transdermal films of donepezil as an alternative delivery approach in Alzheimer's disease treatment. Galipoğlu M; Erdal MS; Güngör S AAPS PharmSciTech; 2015 Apr; 16(2):284-92. PubMed ID: 25273029 [TBL] [Abstract][Full Text] [Related]
19. Effect of ethylcellulose and propylene glycol on the controlled-release performance of glyceryl monooleate-mertronidazole periodontal gel. Sallam AS; Hamudi FF; Khalil EA Pharm Dev Technol; 2015 Mar; 20(2):159-68. PubMed ID: 24262092 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy no advantage in Alzheimer's treatment. Harv Health Lett; 2012 Jun; 37(8):8. PubMed ID: 22774260 [No Abstract] [Full Text] [Related] [Next] [New Search]